KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Gross Margin (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Gross Margin data on record, last reported at 36.5% in Q4 2025.

  • For Q4 2025, Gross Margin rose 51.0% year-over-year to 36.5%; the TTM value through Dec 2025 reached 36.88%, up 36.0%, while the annual FY2025 figure was 36.88%, 36.0% up from the prior year.
  • Gross Margin reached 36.5% in Q4 2025 per AMRX's latest filing, up from 34.92% in the prior quarter.
  • Across five years, Gross Margin topped out at 39.71% in Q2 2021 and bottomed at 30.77% in Q4 2023.
  • Average Gross Margin over 5 years is 35.99%, with a median of 36.05% recorded in 2024.
  • Peak YoY movement for Gross Margin: surged 1183bps in 2021, then plummeted -456bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 30.99% in 2021, then rose by 14bps to 35.32% in 2022, then fell by -13bps to 30.77% in 2023, then grew by 17bps to 35.98% in 2024, then rose by 1bps to 36.5% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 36.5% in Q4 2025, 34.92% in Q3 2025, and 39.51% in Q2 2025.